<DOC>
	<DOCNO>NCT00221624</DOCNO>
	<brief_summary>Response second-line anti-HCV treatment non responder patient first-line dual therapy remain poor . Preliminary study amantadine suggest drug could potentially effective treat hepatitis C .</brief_summary>
	<brief_title>Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Treatment Hepatitis C Infected Patients</brief_title>
	<detailed_description>Background : Response second-line anti-HCV treatment non responder patient first-line dual therapy remain poor . Preliminary study amantadine suggest drug could potentially effective treat hepatitis C. Design : randomize , double-blind , multicenter trial . Interventions compare : Peg-interferon alfa 2A + ribavirin + amantadine versus Peg-interferon alfa 2A + ribavirin + Placebo Eligibility criterion : Chronic hepatitis C , previously treat combination interferon plus ribavirin least 24 week , detectable HCV RNA . primary outcome : sustained virological response , define undetectable HCV RNA level 24 week end anti HCV treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic hepatitis C Previously treat combination interferon plus ribavirin least 24 week Detectable HCV RNA ( i.e . non responder ) Signed informed consent Evidence another cause liver disease Liver cirrhosis ( childPugh stage BMC ) Alcohol consumption &gt; 30g/day woman &gt; 40g/day men ; drug abuse Other serious relevant disorder : psychiatric condition ( especially depression ) , cardiovascular disease , renal decompensation , seizure history , hemoglobinopathy , autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Hepatitis C , chronic</keyword>
	<keyword>HCV infection</keyword>
	<keyword>Treatment failure</keyword>
	<keyword>PEG Interferon</keyword>
	<keyword>( Interferons/therapeutic use</keyword>
	<keyword>Interferon Alfa-2a/adverse effect )</keyword>
	<keyword>ribavirin</keyword>
	<keyword>( Ribavirin/therapeutic use</keyword>
	<keyword>Ribavirin/adverse effect )</keyword>
	<keyword>Amantadine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
</DOC>